Related references
Note: Only part of the references are listed.Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
Anthony R. Cillo et al.
IMMUNITY (2020)
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
Karina Kulangara et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer
Jill M. Brooks et al.
CLINICAL CANCER RESEARCH (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Immunotherapy for head and neck cancer: Recent advances and future directions
John D. Cramer et al.
ORAL ONCOLOGY (2019)
Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma
Yana G. Najjar et al.
JCI INSIGHT (2019)
Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy
Dayana B. Rivadeneira et al.
CLINICAL CANCER RESEARCH (2018)
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris et al.
ORAL ONCOLOGY (2018)
Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)
Tanguy Y. Seiwert et al.
CANCER RESEARCH (2018)
Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy
Barbara Wegiel et al.
FRONTIERS IN ONCOLOGY (2018)
Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma
Douglas J. Hartman et al.
ORAL ONCOLOGY (2018)
Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction
Ende Zhao et al.
NATURE IMMUNOLOGY (2016)
Immune suppressive mechanisms in the tumor microenvironment
David H. Munn et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction (vol 45, pg 374, 2016)
Nicole E. Scharping et al.
IMMUNITY (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Current relevance of hypoxia in head and neck cancer
Marius G. Bredell et al.
ONCOTARGET (2016)
Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity
Nicole E. Scharping et al.
VACCINES (2016)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium
Andrew C. Hoover et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2007)
Share Paper
